knowledge -WSS

knowledge

author：hotspot 2025-09-29 23:04:17 - browse：8448

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration on Monday approved a gene therapy for metachromatic leukodystrophy, a devastating genetic disorder that eats away at affected children’s neurons.

The medicine, marketed as Lenmeldy, is the first treatment for MLD, which is otherwise fatal. Lenmeldy has to be given before symptoms appear or, in some cases, after the first signs of disease, so it won’t be helpful for many patients living with MLD today. But when given in time, it appears to be near-curative, allowing some children to grow up and attend school with unaffected peers.

Lenmeldy is already marketed in Europe, under the name Libmeldy, and has helped a handful of patients in the U.S. who were treated under compassionate use, as their doctors feared they didn’t have time to wait for approval.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： H5N1 bird flu virus started spreading in cows in Texas in December

leisure time

WSS

Naloxone nonprofit donates 200,000 doses after FDA approval

What to know about Virgin Galactic's 1st mission taking paying customers to space

Emergent cuts jobs, executive role in business shake

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

Orangutan used medicinal plant to treat wound, first time ever seen

entertainment

knowledge

focus

Jerome Adams on the need for new antivirals for Covid

Orangutan used medicinal plant to treat wound, first time ever seen

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Man killed during FBI raid in connection with threats against Biden, other officials

DIEP, the 'gold standard' of breast reconstruction, is under threat

Emergent cuts jobs, executive role in business shake

New air purifier tech could be key to improving indoor air quality

Why failed clinical trials don’t always spell doom for a new drug

Activists slam private health insurers over coverage restrictions

Man killed during FBI raid in connection with threats against Biden, other officials

focus

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

Wegovy’s successful heart trial raises vital question about weight loss

South Korea throws huge K

Diversity in clinical trials starts with building trust, experts say

Cancer researcher Catriona Jamieson is sending tumors into space

More tobacco lobbyists active in statehouses

leisure time

explore

focus

focus